Tag
Anticoagulation therapy in adults aged 80 and older with atrial fibrillation is linked to reduced all-cause mortality despite an increased risk of gastrointestinal bleeding, supporting its continued use in selected elderly patients.
The CONDUCT-AF trial demonstrated that conduction system pacing is non-inferior to biventricular pacing for improving LVEF at 6 months in patients with refractory AF and HF undergoing AV node ablation, with procedural advantages favoring CS
Early catheter ablation in atrial fibrillation patients with prior ischemic stroke reduces major adverse cardiovascular events and improves neurological and cognitive outcomes compared to medical therapy, according to a multi-center retrosp
This meta-analysis consolidates data from six RCTs comparing left atrial appendage closure (LAAC) to oral anticoagulation for stroke prevention in atrial fibrillation, highlighting reduced bleeding with LAAC but increased ischemic stroke ri
The EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and long
The ULYSSES trial demonstrates that ultrasound-guided femoral venous puncture markedly lowers vascular access complications compared to conventional palpation-guided techniques in patients undergoing atrial fibrillation ablation, enhancing
This trial evaluated whether atrioventricular node ablation improves outcomes of cardiac resynchronization therapy in heart failure patients with permanent atrial fibrillation, finding no significant benefit over medical rate control.
Breast cancer independently increases atrial fibrillation risk via tumour-secreted ADAM10, which induces atrial fibrosis through the Ephrin B2 signaling pathway, offering a potential new therapeutic target.
This study reveals genotype-specific differences in atrial fibrillation (AF) risk among dilated cardiomyopathy (DCM) patients, highlighting LMNA mutations as a major predictor of incident AF and its association with worse clinical outcomes,
A novel left atrial (LA) staging system, integrating hemodynamic load and contractile function, predicts new-onset atrial fibrillation risk in hypertrophic cardiomyopathy and may guide tailored AF surveillance.
This study analyzes global trends comparing ischemic stroke burdens linked to diabetes and atrial fibrillation, revealing a rising impact of diabetes-related stroke and highlighting the need for targeted interventions.
This Finnish nationwide study demonstrates that patients with atrial flutter have a substantially lower risk of ischaemic stroke compared to those with atrial fibrillation, highlighting important differences in thromboembolic risk profiles
This study reveals distinct left atrial structural and functional changes associated with obesity in atrial fibrillation patients, highlighting a load-related atrial remodeling that may underlie increased risks of atrial fibrillation and he
This article explores the latest evidence on antithrombotic therapy after PCI in patients with atrial fibrillation, highlighting the balance between bleeding risk and prevention of ischemic events.
This prospective registry reveals a significantly increased risk of stroke or transient ischemic attack within 30 days after pulsed field ablation compared to radiofrequency ablation for atrial fibrillation, highlighting important safety co
Clonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient managem
This nationwide Finnish cohort study reveals that gout increases ischemic stroke risk in atrial fibrillation patients, with urate-lowering therapy linked to reduced stroke incidence, underscoring gout’s potential role in stroke risk s
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
This study evaluates the real-world effectiveness and safety of direct oral anticoagulants versus warfarin in Asian patients with atrial fibrillation and mitral stenosis, revealing higher stroke yet lower myocardial infarction risk with DOA
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
